MAPT and Alzheimer disease: Future studies are encouraged to evaluate tau-PET visual reads in large, unselected cohorts, as has been done with amyloid-PET.2 In addition, less than 50% of patients with AD were female, which may be lower than the general population with clinical AD and should be taken into account when interpreting the data.